FDA Approves Johnson & Johnson’s Edurant PED for Pediatric Patients With HIV

Expanded indication for Edurant in combination with other antiretroviral therapies includes treatment-naïve children with HIV-1 RNA <100,000 copies/mL aged at least 2 years and weighing between 14 kg and 25 kg.

Source link
#FDA #Approves #Johnson #amp #Johnsons #Edurant #PED #Pediatric #Patients #HIV